We are in last-stage co-development conversations with a major west coast hospital network, the PI of our study and leader at The Duke Cancer Institute has agreed to champion us at Duke Health and the focal therapy society is engaged with us.
Our current status is that we have bootstrapped our Volatomic Fingerprint for prostate cancer and kidney cancer. Next, we intend to validate our Volatomic Fingerprint for breast cancer and lung cancer. After this, we will GTM for 18-24 months.
Problem or Opportunity
This year 35,000 American men will die from prostate cancer which is the most common male-specific cancer. 1 in 8 men will be diagnosed with prostate cancer in his lifetime.
Only 25% of men complete the recommended yearly screening, driven by the fact that the PSA screening test for cancer is wrong 80% of the time and follow-up tests are unnecessary and extremely invasive.
African Americans are 2x more likely to get and die from prostate cancer.
Solution (product or service)
We identify unique volatile organic compounds found in urine… Just like Sherlock Holmes’s bloodhound, Toby!
Single urine test that detects prostate cancer 4-times more accurately than the incumbent PSA test, at the price of a drug test, and is urine- and not blood-based, which everyone prefers.
Business model
We will license our technology to two types of organizations.
- Value-Based-Care, which 238m or 69% of Americans are part of
- Lab Networks, also known as ‘Reference Labs’
Our licensees will price at $500 per test, which is 20X COGS or 95% GM. There are two benefits to his model. 1) Reimbursement - CPT Codes already available! 2) Purchase Requirements - None… they already own everything!
We estimate an average license $2M per sale to Value-Based-Care organizations and sell to Lab Networks at $50 per test.
